Ozempic and GLP-1 Agonists: The Dark Side of "Miracle Weight Loss Injections"
Ukraine, Dnepr, st. 25 Sicheslavskaya Brigade (Rybinskaya St.), 119 ‑ 120
Ukraine, Dnepr, st. 25 Sicheslavskaya Brigade (Rybinskaya St.), 119 ‑ 120

Ozempic and GLP-1 Agonists: The Dark Side of "Miracle Weight Loss Injections"

Ozempic, Wegovy, Mounjaro: −14.9% body weight in STEP 1, up to 22.5% in SURMOUNT-1, 20% fewer cardiovascular events in SELECT. Titration, muscle preservation and side effects: gastroparesis, pancreatitis, weight regain.

Ozempic and GLP-1 Agonists: The Dark Side of "Miracle Weight Loss Injections"
In trials, semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro) lowered body weight by 14.9% on average (STEP 1) and by up to 22.5% (SURMOUNT-1); the SELECT trial showed a 20% reduction in cardiovascular events. How to raise the dose, how to preserve muscle and which side effects to know about in advance: muscle loss, gastroparesis, pancreatitis, weight regain after stopping.

Key points

Semaglutide (Ozempic/Wegovy), tirzepatide (Mounjaro) and liraglutide (Saxenda) are GLP-1 receptor agonists. The table shows what they give people.

WhereHow it helpsWhat human studies showed
Obesity, semaglutide 2.4 mglowers body weightSTEP 1: −14.9% of body weight on average over 68 weeks (Wilding et al., NEJM, 2021)
Obesity, tirzepatidedual GLP-1 and GIP agonist, lowers body weightSURMOUNT-1: up to 22.5% of body weight (Jastreboff et al., NEJM, 2022)
Heart and blood vessels, semaglutide 2.4 mgfewer cardiovascular eventsSELECT: 20% reduction in cardiovascular events
Type 2 diabetesstimulates insulin secretion—

How it helps

How they work

GLP-1 receptor agonists: 1) slow gastric emptying, 2) suppress appetite in the hypothalamus, 3) stimulate insulin secretion. Semaglutide acts for up to 7 days (vs 2 minutes for native GLP-1). Tirzepatide is a dual GLP-1 and GIP agonist.

Ozempic (up to 2 mg) is for diabetes, Wegovy (2.4 mg) for obesity (one active substance, semaglutide); Mounjaro is tirzepatide.

When GLP-1 agonists are justified

  • BMI > 40 with high cardiovascular risk
  • Type 2 diabetes with inadequate control
  • Proven failure of non-drug interventions over 6-12 months
  • Preparation for bariatric surgery
  • SELECT trial: 20% reduction in cardiovascular events

How to take it

These are prescription drugs that require laboratory monitoring.

Dose titration

Semaglutide (Wegovy) for obesity is titrated on a fixed 16-week schedule: 0.25 mg subcutaneously once weekly × 4 weeks → 0.5 mg × 4 weeks → 1.0 mg × 4 weeks → 1.7 mg × 4 weeks → maintenance dose 2.4 mg. Liraglutide (Saxenda) is injected daily, escalating from 0.6 mg to 3.0 mg in 0.6 mg steps every 7 days. Tirzepatide (Mounjaro/Zepbound) starts at 2.5 mg once weekly, increasing to 5, 7.5, 10, 12.5 and 15 mg at intervals of at least 4 weeks PMID: 35658024.

WeeksSemaglutide dose/week
1–40.25 mg
5–80.5 mg
9–121.0 mg
13–161.7 mg
maintenance2.4 mg

Tests and monitoring

Pre-treatment work-up: complete blood count, biochemistry (ALT, AST, creatinine with eGFR by CKD-EPI, bilirubin, amylase, lipase), fasting glucose, HbA1c, fasting insulin with HOMA-IR, lipid panel, TSH, calcitonin (with a burdened thyroid history or thyroid nodules larger than 1 cm), ultrasound of the thyroid and abdominal organs (to exclude gallstones). A baseline DEXA scan to assess body composition is recommended for patients with BMI < 35 and when therapy is planned for more than 12 months.

Follow-up monitoring: HbA1c, creatinine and liver tests at 3 months, then every 6 months. Lipase only when abdominal symptoms appear; routine screening for asymptomatic hyperlipasaemia is not indicated, because an asymptomatic rise of the enzyme does not correlate with the risk of clinical pancreatitis. Weight and waist circumference monthly. DEXA every 6 months to track the ratio of fat to lean mass.

Criteria for stopping therapy: no weight loss of ≥ 5% after 12 weeks on the maximum tolerated dose; development of any absolute contraindication; pregnancy; persistent impairment of quality of life due to side effects.

How to preserve muscle

Target protein intake is 1.4–1.8 g/kg of ideal body weight per day, spread evenly over 4 meals (25–40 g of leucine-containing protein per meal to activate mTOR signalling). With reduced appetite, reaching this target requires protein concentrates (whey or casein isolate, 25–30 g serving). For patients with BMI > 35 the calculation uses adjusted weight: ideal + 0.4 × (actual − ideal).

Resistance training: at least 2 sessions per week, multi-joint compound exercises (squat, deadlift, press, row), 3–4 sets of 6–12 repetitions to 1–2 repetitions in reserve, progressive overload with an increase in working weight every 2–4 weeks.

Sarcopenia biomarkers to monitor: appendicular lean mass index by DEXA (ALMI; sarcopenia cut-off < 7.0 kg/m² in men, < 5.5 kg/m² in women per the EWGSOP2 consensus); handgrip strength by dynamometer (< 27 kg in men, < 16 kg in women); 4-metre gait speed (< 0.8 m/s indicates functional decline). If ALMI falls by more than 5% from baseline or grip strength drops in a clinically meaningful way — revise the training programme, raise protein to 2.0 g/kg and discuss de-intensifying GLP-1 therapy.

Creatine monohydrate 3–5 g/day is the only nutraceutical with a proven effect on preserving strength during a calorie deficit. Vitamin D is kept at 30–50 ng/mL (75–125 nmol/L) — deficiency is associated with accelerated muscle loss.

Who should see a doctor first

Contraindications

Absolute contraindications to GLP-1 agonists: personal or family history of medullary thyroid carcinoma, multiple endocrine neoplasia type 2 (MEN 2), history of pancreatitis, pregnancy and breastfeeding, severe gastroparesis, hypersensitivity. Relative contraindications: diabetic retinopathy with proliferative changes, gallstone disease, severe renal impairment (eGFR < 15 mL/min/1.73 m²), age under 18 and over 75 (limited data). With established osteoporosis (T-score ≤ −2.5), therapy for weight loss is not started without prior assessment by an endocrinologist.

Pregnancy and breastfeeding: semaglutide is stopped at least 2 months before a planned conception; during breastfeeding the drugs are not recommended. On tirzepatide, use a barrier method of contraception for 4 weeks after starting and after each dose increase.

Nausea and vomiting

Nausea is reported in 44%, vomiting in 24%, diarrhoea in 30% and constipation in 24% of patients on semaglutide 2.4 mg in STEP-1 PMID: 33567185. Symptoms are dose-dependent, peak in the first 4–8 weeks after an escalation and usually resolve within 4–6 weeks if the dose is held. Tactics: with marked nausea, delay the next titration step by an additional 4 weeks; if symptoms persist, return to the previous dose. Reducing portions to 150–200 mL, avoiding fatty and fried food and stopping eating at the first signs of fullness lessen the symptoms. Antiemetics (ondansetron 4 mg as needed) are acceptable as a short course.

Premature discontinuation due to gastrointestinal effects in STEP-1 was 4.5% versus 0.8% on placebo PMID: 33567185. In SURMOUNT-1 the discontinuation rate for tirzepatide 15 mg was 6.2% PMID: 35658024. Criteria for immediate discontinuation: persistent vomiting for more than 48 hours, signs of dehydration, acute epigastric pain (rule out pancreatitis — measure lipase), jaundice (rule out gallstones).

Dehydration from vomiting and reduced oral intake raises the risk of acute kidney injury, especially in patients on ACE inhibitors, ARBs, diuretics or NSAIDs. Creatinine and electrolytes are checked 4 weeks after starting and at every dose escalation in patients with a baseline eGFR of 30–60 mL/min/1.73 m².

Muscle loss

In STEP 1, up to 39% of lost weight was lean mass (Wilding et al., NEJM, 2021, Supplementary). At 15 kg lost, ~6 kg is muscle. Muscle loss lowers basal metabolic rate, creating a metabolic trap after discontinuation.

In STEP-1, lean mass made up 39% of the weight lost according to the DEXA substudy PMID: 33567185. The comparable figure in SURMOUNT-1 for tirzepatide 15 mg is about 25–33% PMID: 35658024. For comparison: when weight is lost through diet plus resistance training, the share of muscle in the weight lost is usually smaller.

"Ozempic face"

Rapid loss of subcutaneous fat on the face: deep nasolabial folds, hollow cheeks, sagging neck. US plastic surgeons report a 40-60% rise in requests for "post-Ozempic" procedures in 2024.

Pancreatitis and cancer risks

FDA boxed warning on the risk of medullary thyroid carcinoma. Preclinical rodent studies showed C-cell tumours. The drugs are contraindicated in MEN 2.

Severe upper abdominal pain radiating to the back, with nausea and vomiting, is a reason to stop the injections immediately and go to hospital. Test results where the decision rests with the doctor: calcitonin > 100 pg/mL — medullary carcinoma is ruled out first (thyroid ultrasound, fine-needle biopsy); triglycerides > 5.6 mmol/L (500 mg/dL) — a relative contraindication because of the risk of pancreatitis; lipase above 3 times the upper limit of normal together with symptoms — immediate discontinuation and CT of the pancreas.

Gastroparesis and surgery

Slowed gastric emptying may become irreversible. Sodhi et al. (JAMA, 2023) described cases of persistent gastroparesis after discontinuation. The American Society of Anesthesiologists recommends stopping GLP-1 agonists one week before elective surgery.

Delayed gastric emptying under GLP-1 agonists raises the risk of regurgitation of gastric contents and aspiration at induction of anaesthesia. Sodhi et al. showed a 3.67-fold higher risk of persistent gastroparesis in patients on GLP-1 agonists (semaglutide, liraglutide) compared with bupropion-naltrexone PMID: 37796527. In 2023 the American Society of Anesthesiologists (ASA) recommended: for weekly drugs (semaglutide, dulaglutide, tirzepatide), skip the dose 7 days before an elective procedure under general anaesthesia or deep sedation; for daily drugs (liraglutide), stop 24 hours before. In emergency surgery, assume a "full stomach" regardless of fasting time, use rapid sequence induction with the Sellick manoeuvre and, where possible, postpone the procedure by 12–24 hours and perform gastroscopy to assess gastric contents.

Endoscopic procedures under sedation: if the GLP-1 dose is continued within 7 days before upper endoscopy, 25–50% of patients have a significant residual volume of gastric contents even with adequate fasting. For patients on therapy, extend fasting to 24 hours for liquids and 48 hours for solid food; the alternative is a targeted pause one week before.

Tell every clinician who performs anaesthesia or sedation — surgeon, anaesthesiologist, gastroenterologist, dentist — that you are on the injections. After a break of more than 4 weeks, treatment is restarted at a lower dose and titrated up gradually again.

Medicines and alcohol

Clinically significant drug interactions: delayed gastric emptying can alter absorption of oral drugs with a narrow therapeutic window — warfarin (check INR 2–4 weeks after starting), levothyroxine (check TSH after 6–8 weeks), oral contraceptives (consider barrier methods for the first 4 weeks after starting or escalating). Phenytoin, carbamazepine, ciclosporin, tacrolimus — monitor their blood concentrations after starting a GLP-1 agonist. Co-prescribed insulin or sulfonylureas require a pre-emptive dose reduction of 20–30% to avoid hypoglycaemia. Combining with DPP-4 inhibitors (sitagliptin, linagliptin) is irrational: both classes act on the GLP-1 axis, there is no added effect and the risk of side effects adds up.

Alcohol: GLP-1 agonists slow gastric emptying, raising peak ethanol concentrations; patients report a marked reduction in alcohol tolerance and craving — the effect is being studied as a potential indication in alcohol use disorder.

Mental health effects

EMA investigation (2023) into a link with suicidal thoughts. GLP-1 receptors are present in the limbic system and the reward system. Patients report anhedonia — loss of the ability to feel pleasure. A history of anorexia or bulimia carries a risk of relapse because of the sharp drop in appetite.

After stopping

Wilding et al. (Diabetes, Obesity and Metabolism, 2022): within a year of stopping, patients regained about 2/3 of the weight lost. Basal metabolic rate is reduced because of muscle loss — the body burns fewer calories with the same appetite.

GLP-1 agonists do not eliminate insulin resistance — the root cause of metabolic disorders; they act on the consequence (weight) without touching the cause. Prolonged stimulation of beta cells carries a risk of exhausting the islet apparatus.

Bottom line

GLP-1 agonists lower body weight substantially, and in SELECT semaglutide also reduced the number of cardiovascular events. They are prescribed according to indications, the dose is raised gradually under laboratory monitoring, and muscle is protected with resistance training and protein.

Strategies to correct insulin resistance — managing the carbohydrate load, intermittent fasting, resistance training, normalising sleep, metformin, berberine and other glucose-lowering agents — eliminate the metabolic basis without lifelong dependence.

Source: Ozempic and GLP-1 Agonists: The Dark Side of "Miracle Weight Loss Injections" — universum.earth. md_pereligyn — Перелыгин Владимир Игоревич.

Come back
Request a call back